Table of Contents
Table of Contents
Shock is a life-threatening state of acute circulatory failure resulting in inadequate cellular oxygen delivery relative to metabolic demand. Left uncorrected, cellular hypoxia transitions aerobic metabolism to anaerobic glycolysis, producing systemic lactic acidosis, severe cellular dysfunction, end-organ ischemia, and ultimate multi-organ dysfunction syndrome (MODS).
Mastering shock management requires a deep understanding of hemodynamic profiling, early recognition of systemic hypoperfusion, and targeted etiology-specific resuscitation.
1. The Universal Cellular Pathophysiology of Shock
Regardless of etiology, all shock states converge on a final common pathway at the cellular level:
- Oxygen Delivery (DO₂) vs. Oxygen Consumption (VO₂)
Oxygen delivery is determined by Cardiac Output (CO) and Arterial Oxygen Content (CaO₂). When DO₂ falls below a critical threshold, cells can no longer sustain oxidative phosphorylation in the mitochondria. - Anaerobic Metabolism and Lactic Acidosis
In the absence of adequate oxygen, pyruvate is converted to lactate by lactate dehydrogenase rather than entering the Krebs cycle. This generates a net yield of only 2 ATP molecules per glucose molecule (compared to ~36 ATP under aerobic conditions). ATP depletion leads to failure of the Na⁺/K⁺-ATPase pump, intracellular sodium and water accumulation, cell swelling, membrane rupture, and cellular death. - Microvascular Dysfunction and Inflammatory Cascade
Cellular injury releases Damage-Associated Molecular Patterns (DAMPs), triggering endothelial activation, microvascular thrombosis, impaired capillary autoregulation, and progressive tissue ischemia.
2. Classification and Specific Pathophysiology of Shock States
Shock is broadly categorized into four primary physiological phenotypes:
A. Hypovolemic Shock
Critical reduction in intravascular volume → decreased preload → reduced stroke volume → compromised cardiac output.
- Hemorrhagic: Trauma, GI bleeding, ruptured AAA, massive PPH
- Non-hemorrhagic: Severe dehydration, vomiting/diarrhea, DKA, third-spacing (pancreatitis, burns)
Pathophysiology: ↓ Venous Return → ↓ EDV → ↓ SV → Compensatory tachycardia + ↑ SVR
B. Cardiogenic Shock
Primary cardiac pump failure → inadequate CO despite adequate preload.
- Etiologies: AMI (>40% LV impairment), papillary muscle rupture, acute severe MR/AR, end-stage DCM, myocarditis, sustained VT/VF
Pathophysiology: ↓ Contractility → ↓ SV & CI (<2.2 L/min/m²) → ↑ LVEDP & PCWP (>15–18 mmHg) → Pulmonary edema + ↑ SVR
Distributive Shock
Severe peripheral vasodilation + relative hypovolemia (normal or high CO).
C. Septic Shock
: Dysregulated host response → NO-mediated vasodilation + microvascular thrombosis
D. Neurogenic Shock
: High cervical/upper thoracic SCI (≥T6) → loss of sympathetic tone → unopposed vagal tone (hypotension + bradycardia)
Key Takeaway: Loss of sympathetic tone → Low SVR paired uniquely with Severe Bradycardia → First-line: Pure Alpha-1 Phenylephrine & Atropine.E. Anaphylactic Shock
IgE-mediated histamine release → rapid vasodilation, capillary leak, bronchospasm, airway edema
F. Obstructive Shock
- Etiologies: Massive PE, tension pneumothorax, cardiac tamponade, constrictive pericarditis
Pathophysiology: Mechanical impedance → impaired filling/outflow → ↓ CO → ↑ compensatory SVR
3. Hemodynamic Profiles Comparison
Hemodynamic monitoring via Central Venous Catheters or Pulmonary Artery Catheters (Swan-Ganz) allows precise differentiation of shock states:
Hypovolemic Shock
- Central Venous Pressure (CVP): Decreased (<2–6 mmHg)
- Pulmonary Capillary Wedge Pressure (PCWP): Decreased (<8–12 mmHg)
- Cardiac Output / Cardiac Index (CO/CI): Decreased
- Systemic Vascular Resistance (SVR): Elevated (>1200 dynes/sec/cm⁻⁵)
- Mixed Venous Oxygen Saturation (SvO₂): Decreased (<65%)
Cardiogenic Shock
- Central Venous Pressure (CVP): Elevated (>10–12 mmHg)
- Pulmonary Capillary Wedge Pressure (PCWP): Severely Elevated (>15–18 mmHg)
- Cardiac Output / Cardiac Index (CO/CI): Severely Decreased (<2.2 L/min/m²)
- Systemic Vascular Resistance (SVR): Severely Elevated
- Mixed Venous Oxygen Saturation (SvO₂): Severely Decreased (<55%)
Distributive Shock (Early / Hyperdynamic Septic Shock)
- Central Venous Pressure (CVP): Normal or Decreased
- Pulmonary Capillary Wedge Pressure (PCWP): Normal or Decreased
- Cardiac Output / Cardiac Index (CO/CI): Normal or Elevated (>4.0 L/min/m²)
- Systemic Vascular Resistance (SVR): Severely Decreased (<800 dynes/sec/cm⁻⁵)
- Mixed Venous Oxygen Saturation (SvO₂): Elevated (>70% due to impaired tissue oxygen extraction)
Obstructive Shock (Massive PE / Tamponade)
- Central Venous Pressure (CVP): Elevated
- Pulmonary Capillary Wedge Pressure (PCWP): Decreased (in PE) or Equalized with CVP (in Tamponade)
- Cardiac Output / Cardiac Index (CO/CI): Decreased
- Systemic Vascular Resistance (SVR): Elevated
- Mixed Venous Oxygen Saturation (SvO₂): Decreased
4. Evidence-Based Resuscitation and Pharmacotherapy Protocols
Resuscitation goals across all shock types focus on restoring Mean Arterial Pressure (MAP) ≥65 mmHg, normalizing serum lactate levels, achieving urine output ≥0.5 mL/kg/hr, and ensuring adequate arterial oxygen saturation.
A. Fluid Resuscitation
- Distributive & Hypovolemic Shock: Initial rapid fluid administration of 30 mL/kg of balanced crystalloids (e.g., Lactated Ringer’s or Plasma-Lyte) within the first 3 hours. Avoid normal saline (0.9% NaCl) in massive resuscitation to prevent hyperchloremic metabolic acidosis.
- Cardiogenic Shock: Fluid boluses must be administered with extreme caution (125–250 mL trial) or held entirely if PCWP >18 mmHg or pulmonary edema is present.
- Hemorrhagic Shock: Implement Massive Transfusion Protocols (MTP) with a 1:1:1 ratio of Packed Red Blood Cells (PRBCs), Fresh Frozen Plasma (FFP), and Platelets. Minimize crystalloid infusion to prevent dilutional coagulopathy.
B. Vasoactive and Inotropic Agent Protocol
- Norepinephrine (First-Line Vasopressor)
- Mechanism: Potent Alpha-1 agonist (vasoconstriction) with moderate Beta-1 agonist effects (inotropy).
- Indications: First-line agent for Septic, Cardiogenic, and Hypovolemic shock refractory to initial fluid resuscitation.
- Dosing: Initiate at 0.02–0.05 mcg/kg/min IV; titrate rapidly to maintain MAP ≥65 mmHg.
- Vasopressin (Second-Line / Adjunct Vasopressor)
- Mechanism: Direct stimulation of V1a receptors on vascular smooth muscle, restoring vascular tone independently of adrenergic receptors.
- Indications: Added to Norepinephrine in Septic Shock to increase MAP or reduce Norepinephrine dosage requirements.
- Dosing: Fixed non-titratable dose of 0.03 units/min IV.
- Epinephrine (Second-Line Vasopressor / Anaphylaxis First-Line)
- Mechanism: Potent Beta-1, Beta-2, and Alpha-1 agonist.
- Indications: First-line intramuscular (IM) agent for Anaphylactic Shock (0.3–0.5 mg IM 1:1000 concentration). Add as an intravenous infusion in refractory Septic Shock or severe Anaphylaxis.
- Dosing: IV infusion at 0.01–0.1 mcg/kg/min.
- Dobutamine (First-Line Inotrope)
- Mechanism: Predominant Beta-1 agonist (increases myocardial contractility and heart rate) with mild Beta-2 vasodilation.
- Indications: Cardiogenic shock with low Cardiac Index (<2.2 L/min/m²) and elevated left ventricular filling pressures, or Septic Shock with persistent hypoperfusion despite adequate volume and MAP.
- Dosing: Initiate at 2.5–5.0 mcg/kg/min; titrate up to 20 mcg/kg/min. (May cause hypotension if patient is hypovolemic).
- Milrinone (Inodilator)
- Mechanism: Phosphodiesterase-3 (PDE-3) inhibitor; increases intracellular cAMP, enhancing myocardial contractility while causing systemic and pulmonary vasodilation.
- Indications: Severe cardiogenic shock, especially with concurrent pulmonary hypertension or in patients on chronic beta-blocker therapy.
- Dosing: 0.25–0.75 mcg/kg/min IV. Requires renal dose adjustment.
- Phenylephrine (Pure Alpha-1 Agonist)
- Mechanism: Pure vascular smooth muscle Alpha-1 constriction with no cardiac Beta activity.
- Indications: Neurogenic shock, severe tachyarrhythmias limiting Norepinephrine use, or salvage therapy when SVR remains low.
C. Targeted Etiology-Specific Interventions
- Septic Shock: Administer broad-spectrum empiric IV antibiotics within 1 hour of recognition. Source control (abscess drainage, line removal, surgical debridement) as early as possible. Consider IV Hydrocortisone (200 mg/day) if refractory to vasopressors.
- Cardiogenic Shock: Emergency revascularization (Percutaneous Coronary Intervention [PCI] or CABG) for acute MI. Mechanical Circulatory Support (Impella, Intra-Aortic Balloon Pump [IABP], or Veno-Arterial ECMO) for severe refractory hemodynamic collapse.
- Obstructive Shock: Immediate needle decompression followed by chest tube placement for Tension Pneumothorax; Emergency Pericardiocentesis for Cardiac Tamponade; Systemic Thrombolysis (Alteplase) or Surgical Embolectomy for massive Pulmonary Embolism.
5. Summary Bedside Action Matrix for Clinicians
- MAP Target: Maintain MAP ≥65 mmHg using Norepinephrine as the primary vasopressor across most shock categories.
- Assess Preload & Volume Responsiveness: Use dynamic measures (Passive Leg Raise, Stroke Volume Variation [SVV], Pulse Pressure Variation [PPV]) before continuing aggressive fluid resuscitation.
- Cardiogenic Component: If Cardiac Index remains <2.2 L/min/m² despite adequate MAP, add Dobutamine.
- Distributive Vasoplegia: If Norepinephrine requirements exceed 0.25 mcg/kg/min, add Vasopressin at 0.03 units/min.
- Etiology Resolution: Vasopressors only buy time; definitive reversal requires treating the underlying cause (Antibiotics, Source Control, PCI, Revascularization, Decompression, Blood Transfusion).
G. Hemodynamic Cheat Sheet & Chart
| Shock Type | CO | CVP | SVR | HR | Primary Cause / Key Clinical Feature | First-Line Intervention |
|---|---|---|---|---|---|---|
| Hypovolemic | ↓ | ↓ | ↑ | ↑ | Intravascular volume loss (hemorrhage/dehydration) | Rapid IV fluids & blood products |
| Cardiogenic | ↓ | ↑ | ↑ | ↑ | Primary pump failure (MI, severe HF) | Inotropes (Dobutamine) & revascularization |
| Septic | ↑ (early) / ↓ (late) | ↓ | ↓↓ | ↑ | Endotoxin-mediated massive vasodilation & microclots | Norepinephrine & IV fluids |
| Neurogenic | ↓ | ↓ | ↓↓ | ↓ | Loss of sympathetic tone (spinal cord trauma) | Phenylephrine & Atropine |
| Anaphylactic | ↓ | ↓ | ↓↓ | ↑ | Type 1 hypersensitivity, airway edema & capillary leak | Intramuscular Epinephrine |
| Obstructive | ↓ | ↑ | ↑ | ↑ | Physical mechanical barrier (PE, Tamponade, Tension PTX) | Mechanical decompression / Thrombolysis |
References
Annane, D., Ouanes-Besbes, L., de Backer, D., Du, B., Gordon, A. C., Hernandez, G., … & Olsen, K. M. (2018). Tripartite consensus on sepsis and septic shock in resource-limited settings. Intensive Care Medicine, 44(9), 1240–1257.
Cecconi, M., De Backer, D., Antonelli, M., Beale, R., Bakker, J., Hofer, C., … & Vincent, J. L. (2014). Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Medicine, 40(12), 1795–1815.
Evans, L., Rhodes, A., Alhazzani, W., Antonini, M. V., Coopersmith, C. M., French, C., … & Levy, M. M. (2021). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Critical Care Medicine, 49(11), e1063–e1143.
Hollenberg, S. M. (2019). Vasoactive drugs in circulatory shock. American Journal of Respiratory and Critical Care Medicine, 199(9), 1167–1170.
Thiele, H., Ohman, E. M., de Waha-Thiele, S., Zeymer, U., & Desch, S. (2019). Management of cardiogenic shock complicating acute myocardial infarction. European Heart Journal, 40(32), 2671–2683.